Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

306 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term efficacy of mepolizumab in patients with eosinophilic granulomatosis with polyangiitis: a propensity score matching analysis in the multicenter REVEAL cohort study.
Shiomi M, Watanabe R, Matsuda S, Kotani T, Okazaki A, Masuda Y, Yoshida T, Shoji M, Tsuge R, Kadoba K, Hiwa R, Yamamoto W, Takeda A, Itoh Y, Hashimoto M. Shiomi M, et al. Among authors: yamamoto w. Front Immunol. 2024 Oct 2;15:1457202. doi: 10.3389/fimmu.2024.1457202. eCollection 2024. Front Immunol. 2024. PMID: 39416779 Free PMC article.
Prognostic Factors Affecting Death in Patients with Rheumatoid Arthritis Complicated by Pneumocystis jirovecii Pneumonia and One-Year Clinical Course: The ANSWER Cohort Study.
Shiba H, Kotani T, Nagai K, Hata K, Yamamoto W, Yoshikawa A, Wada Y, Hiramatsu Y, Makino H, Ueda Y, Onishi A, Murata K, Amuro H, Son Y, Hara R, Hirano T, Ebina K, Katayama M, Hashimoto M, Takeuchi T. Shiba H, et al. Among authors: yamamoto w. Int J Mol Sci. 2023 Apr 17;24(8):7399. doi: 10.3390/ijms24087399. Int J Mol Sci. 2023. PMID: 37108561 Free PMC article.
IL-6 inhibitors and JAK inhibitors as favourable treatment options for patients with anaemia and rheumatoid arthritis: ANSWER cohort study.
Nakayama Y, Watanabe R, Yamamoto W, Ebina K, Hirano T, Kotani T, Shiba H, Katayama M, Son Y, Amuro H, Onishi A, Jinno S, Hara R, Murakami K, Murata K, Ito H, Tanaka M, Matsuda S, Morinobu A, Hashimoto M. Nakayama Y, et al. Among authors: yamamoto w. Rheumatology (Oxford). 2024 Feb 1;63(2):349-357. doi: 10.1093/rheumatology/kead299. Rheumatology (Oxford). 2024. PMID: 37354495
Predictive value of baseline concomitant glucocorticoid for abatacept-mediated long-term inhibition of radiographic progression: insights from the KURAMA cohort.
Murakami K, Watanabe R, Fujisaki T, Ito H, Murata K, Yamamoto W, Fujii T, Onizawa H, Onishi A, Tanaka M, Hashimoto M, Morinobu A. Murakami K, et al. Among authors: yamamoto w. Immunol Med. 2024 Mar;47(1):45-51. doi: 10.1080/25785826.2023.2265148. Epub 2023 Oct 3. Immunol Med. 2024. PMID: 37789658
Trends of disease activity in Japanese patients over 75 years with rheumatoid arthritis from 2014 to 2021: the ANSWER cohort study.
Yamada H, Jinno S, Maeda T, Hayashi S, Yamamoto W, Onishi A, Onizawa H, Takeuchi T, Hiramatsu Y, Okita Y, Ebina K, Son Y, Yoshida N, Watanabe R, Hara R, Yamashita M, Nose Y, Yamamoto Y, Okano T, Nishimura K, Ueda Y, Sendo S, Hashimoto M, Kuroda R, Saegusa J. Yamada H, et al. Among authors: yamamoto y, yamamoto w. Rheumatology (Oxford). 2024 Aug 1;63(8):2147-2151. doi: 10.1093/rheumatology/kead539. Rheumatology (Oxford). 2024. PMID: 37792494
Real-world comparative study of the efficacy of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study.
Hayashi S, Tachibana S, Maeda T, Yamashita M, Shirasugi I, Yamamoto Y, Yamada H, Okano T, Nishimura K, Ueda Y, Jinno S, Saegusa J, Yamamoto W, Murata K, Fujii T, Hata K, Yoshikawa A, Ebina K, Etani Y, Yoshida N, Amuro H, Hashimoto M, Hara R, Katayama M, Okano T, Kuroda R. Hayashi S, et al. Among authors: yamamoto y, yamamoto w. Rheumatology (Oxford). 2024 Nov 1;63(11):3033-3041. doi: 10.1093/rheumatology/kead543. Rheumatology (Oxford). 2024. PMID: 37924201
Comparative effectiveness of biological disease-modifying antirheumatic drugs and Janus kinase inhibitor monotherapy in rheumatoid arthritis.
Onishi A, Yamada H, Yamamoto W, Watanabe R, Hara R, Katayama M, Okita Y, Maeda Y, Amuro H, Son Y, Yoshikawa A, Hata K, Hashimoto M, Saegusa J, Morinobu A. Onishi A, et al. Among authors: yamamoto w. Rheumatology (Oxford). 2024 Nov 1;63(11):3065-3073. doi: 10.1093/rheumatology/kead620. Rheumatology (Oxford). 2024. PMID: 37988163
306 results